| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Rabie Karrouri, Zakaria Hammani, Roukaya Benjelloun, Yassine Othema. Major depressive disorder: Validated treatments and future challenges. World journal of clinical cases. vol 9. issue 31. 2021-12-11. PMID:34877271. |
pharmacotherapy, especially selective serotonin reuptake inhibitors antidepressants, remains the most frequent option for treating depression during the acute phase, while other promising pharmacological options are still competing for the attention of practitioners. |
2021-12-11 |
2023-08-13 |
Not clear |
| Marta Ielmini, Ivano Caselli, Francesca Ceccon, Marcello Diurni, Nicola Poloni, Camilla Callegar. Selective Serotonin Reuptake Inhibitors and Nutraceutical Combination in Major Depression Disorder: A Case-Control Study. Psychopharmacology bulletin. vol 51. issue 4. 2021-12-11. PMID:34887597. |
selective serotonin reuptake inhibitors and nutraceutical combination in major depression disorder: a case-control study. |
2021-12-11 |
2023-08-13 |
Not clear |
| R B Malvestio, P Medeiros, S E Negrini-Ferrari, M Oliveira-Silva, A C Medeiros, C M Padovan, L Luongo, S Maione, N C Coimbra, R L de Freita. Cannabidiol in the prelimbic cortex modulates the comorbid condition between the chronic neuropathic pain and depression-like behaviour in rats: The role of medial prefrontal cortex 5-HT Brain research bulletin. vol 174. 2021-12-10. PMID:34192579. |
cannabidiol in the prelimbic cortex modulates the comorbid condition between the chronic neuropathic pain and depression-like behaviour in rats: the role of medial prefrontal cortex 5-ht the prelimbic division (prl) of the medial prefrontal cortex (mpfc) is a cerebral division that is putatively implicated in the chronic pain and depression. |
2021-12-10 |
2023-08-13 |
rat |
| Jeffrey R Strawn, Jeffrey A Mills, Vikram Suresh, Tara S Peris, John T Walkup, Paul E Croarki. Combining selective serotonin reuptake inhibitors and cognitive behavioral therapy in youth with depression and anxiety. Journal of affective disorders. vol 298. issue Pt A. 2021-12-07. PMID:34728290. |
combining selective serotonin reuptake inhibitors and cognitive behavioral therapy in youth with depression and anxiety. |
2021-12-07 |
2023-08-13 |
Not clear |
| Maria Sidorova, Golo Kronenberg, Susann Matthes, Markus Petermann, Rainer Hellweg, Oksana Tuchina, Michael Bader, Natalia Alenina, Friederike Klempi. Enduring Effects of Conditional Brain Serotonin Knockdown, Followed by Recovery, on Adult Rat Neurogenesis and Behavior. Cells. vol 10. issue 11. 2021-12-07. PMID:34831469. |
on/off stimulations of 5-ht concentrations might uniquely mirror the clinical course of major depression (e.g., relapse after discontinuation of antidepressants) in humans. |
2021-12-07 |
2023-08-13 |
rat |
| Selin Acar, Hilal Erol, Elif Keskin Arslan, Nusret Uysal, Barış Karadaş, Tijen Kaya Temiz, Yusuf Cem Kapla. Paroxetine overdose during pregnancy. Forensic sciences research. vol 6. issue 3. 2021-12-07. PMID:34868717. |
paroxetine is a selective serotonin reuptake inhibitor (ssri) used in the treatment of depression and anxiety disorders. |
2021-12-07 |
2023-08-13 |
Not clear |
| Xin Huang, Hang Yin, Xin-Xing Wan, Bing Fu, Bei Tang, Jun Le. Maternal plasma serotonin level not suitable as postpartum depression diagnostic biomarker: Results from a prospective cohort study. Journal of affective disorders. vol 298. issue Pt A. 2021-12-06. PMID:34748824. |
maternal plasma serotonin level not suitable as postpartum depression diagnostic biomarker: results from a prospective cohort study. |
2021-12-06 |
2023-08-13 |
Not clear |
| Xin Huang, Hang Yin, Xin-Xing Wan, Bing Fu, Bei Tang, Jun Le. Maternal plasma serotonin level not suitable as postpartum depression diagnostic biomarker: Results from a prospective cohort study. Journal of affective disorders. vol 298. issue Pt A. 2021-12-06. PMID:34748824. |
whether plasma serotonin (5-ht) levels could be a biomarker for postpartum depression (ppd) diagnosis is under dispute. |
2021-12-06 |
2023-08-13 |
Not clear |
| Carolin A Lewis, Karsten Mueller, Rachel G Zsido, Janis Reinelt, Ralf Regenthal, Hadas Okon-Singer, Erika E Forbes, Arno Villringer, Julia Sache. A single dose of escitalopram blunts the neural response in the thalamus and caudate during monetary loss. Journal of psychiatry & neuroscience : JPN. vol 46. issue 3. 2021-12-05. PMID:33904667. |
selective serotonin reuptake inhibitors (ssris) show acute effects on the neural processes associated with negative affective bias in healthy people and people with depression. |
2021-12-05 |
2023-08-13 |
Not clear |
| Susannah E Murphy, Angharad N de Cates, Amy L Gillespie, Beata R Godlewska, Jessica C Scaife, Lucy C Wright, Philip J Cowen, Catherine J Harme. Translating the promise of 5HT Psychological medicine. vol 51. issue 7. 2021-11-30. PMID:32241310. |
translating the promise of 5ht animal experimental studies suggest that 5-ht4 receptor activation holds promise as a novel target for the treatment of depression and cognitive impairment. |
2021-11-30 |
2023-08-13 |
Not clear |
| Yilin Li, Yang Wang, Na Zhang, Shenzhi Zhou, Ying Peng, Jiang Zhen. Glutathione conjugation and protein modification resulting from metabolic activation of venlafaxine Xenobiotica; the fate of foreign compounds in biological systems. vol 51. issue 11. 2021-11-30. PMID:34160341. |
glutathione conjugation and protein modification resulting from metabolic activation of venlafaxine venlafaxine (vlf), an antidepressant agent, is widely used to combat major depressive disorders, particularly for the treatment of selective serotonin reuptake inhibitor-resistant depression. |
2021-11-30 |
2023-08-13 |
mouse |
| Mario Gennaro Mazza, Raffaella Zanardi, Mariagrazia Palladini, Patrizia Rovere-Querini, Francesco Benedett. Rapid response to selective serotonin reuptake inhibitors in post-COVID depression. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 54. 2021-11-29. PMID:34634679. |
rapid response to selective serotonin reuptake inhibitors in post-covid depression. |
2021-11-29 |
2023-08-13 |
Not clear |
| Mario Gennaro Mazza, Raffaella Zanardi, Mariagrazia Palladini, Patrizia Rovere-Querini, Francesco Benedett. Rapid response to selective serotonin reuptake inhibitors in post-COVID depression. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 54. 2021-11-29. PMID:34634679. |
we aim to investigate the efficacy of selective serotonin reuptake inhibitor (ssri) in treating post-covid depression. |
2021-11-29 |
2023-08-13 |
Not clear |
| Ahmed Hassen Elshafeey, Rania Moataz El-Dahm. Formulation and Development of Oral Fast-Dissolving Films Loaded with Nanosuspension to Augment Paroxetine Bioavailability: In Vitro Characterization, Ex Vivo Permeation, and Pharmacokinetic Evaluation in Healthy Human Volunteers. Pharmaceutics. vol 13. issue 11. 2021-11-29. PMID:34834284. |
paroxetine (px) is the most potent serotonin reuptake inhibitor utilized in depression and anxiety treatment. |
2021-11-29 |
2023-08-13 |
human |
| Mathilde Baudat, Anne R de Kort, Daniel L A van den Hove, Elbert A J Jooste. Early-life exposure to selective serotonin reuptake inhibitors: long-term effects on pain and affective comorbidities. The European journal of neuroscience. 2021-11-29. PMID:34841582. |
a growing body of evidence indicate that early-life exposure to selective serotonin reuptake inhibitor has long-term consequences on the offspring's pain in addition to affective disorders like anxiety disorder and major depression. |
2021-11-29 |
2023-08-13 |
Not clear |
| Shvetank Bhatt, Thangaraj Devadoss, Santhepete Nanjundaiah Manjula, Jayaraman Rajanga. 5-HT Current neuropharmacology. vol 19. issue 9. 2021-11-25. PMID:33059577. |
5-ht depression or major depressive disorder (mdd) is a prolonged condition of sadness. |
2021-11-25 |
2023-08-13 |
Not clear |
| Shvetank Bhatt, Thangaraj Devadoss, Santhepete Nanjundaiah Manjula, Jayaraman Rajanga. 5-HT Current neuropharmacology. vol 19. issue 9. 2021-11-25. PMID:33059577. |
according to the monoamine hypothesis, serotonin (5-hydroxy tryptamine, 5-ht), dopamine (da) and norepinephrine (ne) are the major neurotransmitters (nts) involved in depression. |
2021-11-25 |
2023-08-13 |
Not clear |
| Sarah Delcourte, Adeline Etievant, Nasser Haddjer. Role of central serotonin and noradrenaline interactions in the antidepressants' action: Electrophysiological and neurochemical evidence. Progress in brain research. vol 259. 2021-11-24. PMID:33541681. |
although the pathophysiology of major depression (md) is not fully understood, numerous investigations have suggested that treatments with various classes of antidepressant drugs may lead to an enhanced 5-ht and/or adapted na neurotransmissions. |
2021-11-24 |
2023-08-13 |
Not clear |
| Rabail Altaf, Irasema Gonzalez, Kimberley Rubino, Eric C Neme. Folate as adjunct therapy to SSRI/SNRI for major depressive disorder: Systematic review & meta-analysis. Complementary therapies in medicine. vol 61. 2021-11-24. PMID:34450256. |
evaluate depression scores, response, and remission rates in patients with major depression receiving adjunct therapy with folate (l-methylfolate or folic acid) compared to selective serotonin reuptake inhibitor or serotonin-norepinephrine reuptake inhibitor (ssri or snri) monotherapy. |
2021-11-24 |
2023-08-13 |
Not clear |
| Stephen Daniels, Danielle Lemaire, Thomas Lapointe, Cheryl Limebeer, Linda Parker, Francesco Ler. Effects of inescapable stress on responses to social incentive stimuli and modulation by escitalopram. Psychopharmacology. vol 238. issue 11. 2021-11-23. PMID:34328518. |
moreover, there are questions about the effectiveness of selective serotonin reuptake inhibitors (ssris) on improving social hedonic functioning deficits characteristic of major depression. |
2021-11-23 |
2023-08-13 |
Not clear |